



CLINICAL COMPENDIUM: REAL WORLD CLINICAL CASE STUDIES ON THE TREATMENT OF MENOPAUSAL SYMPTOMS: AN INTERACTIVE EDUCATIONAL ACTIVITY

References

Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA*. 2004;291(14):1701-1712. doi:10.1001/jama.291.14.1701

Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA Intern Med*. 2015;175(4):531-539. doi:10.1001/jamainternmed.2014.8063

Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. *Menopause*. 2012;19(7):749-759. doi:10.1097/gme.0b013e31823fe835

Bevry ML, Stogdill ER, Lea CM, et al. Addressing menopause symptoms in the primary care setting: Opportunity to bridge care delivery gaps. *Menopause*. 2024;31(12):1044-1048. doi:10.1097/GME.0000000000002439

Cho L, Kaunitz AM, Faubion SS, et al. Rethinking menopausal hormone therapy: For whom, what, when, and how long? *Circulation*. 2023;147(7):597-610. doi:10.1161/CIRCULATIONAHA.122.061559

Freedman RR. Pathophysiology and treatment of menopausal hot flashes. *Semin Reprod Med*. 2005;23(2):117-125. doi:10.1055/s-2005-869479

Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. *Menopause*. 2014;21(9):924-932. doi:10.1097/GME.0000000000000196

Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: A phase 3 RCT. *J Clin Endocrinol Metab*. 2023;108(8):1981-1997. doi:10.1210/clinem/dgad058

Khan SJ, Kapoor E, Faubion SS, Kling JM. Vasomotor symptoms during menopause: A practical guide on current treatments and future perspectives. *Int J Womens Health*. 2023;15:273-287. doi:10.2147/IJWH.S365808

Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women's Health Initiative randomized trials. *JAMA*. 2017;318(10):927-938. doi:10.1001/jama.2017.11217

Padilla SL, Johnson CW, Barker FD, Patterson MA, Palmiter RD. A neural circuit underlying the generation of hot flashes. *Cell Rep*. 2018;24(2):271-277. doi:10.1016/j.celrep.2018.06.037

Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. *Am J Obstet Gynecol*. 2007;196(2):97-106. doi:10.1016/j.ajog.2006.05.056

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288(3):321-333. doi:10.1001/jama.288.3.321

Sarri G, et al. Diagnosis and management of menopause: summary of NICE guidance. *BMJ*. 2015;351:h5746. doi:10.1136/bmj.h5746

Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236

"The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause*. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028

"The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. *Menopause*. 2023;30(6):573-590. doi:10.1097/GME.0000000000002200

Veozah. Prescribing information. Astellas Pharma US, Inc. December 2024. Accessed December 20, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216578s004lbl.pdf.